BriaCell Therapeutics Corp. (BCTX) Stock Price & Analysis
BriaCell Therapeutics Corp. (BCTX) closed at USD 3.77 on Thursday, October 15, 2026, up 2.03% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.69; the Oct 15, 2026 session ranged USD 3.7–3.81 on volume of 34,328 shares. Market capitalization is $32.75M, with a 52-week range of USD 2.6–14.68 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BCTX.md
Key facts (BCTX)
- Analysts: None.
- Total return with dividends: 1Y -69.4% vs S&P 500 +18.1%; 5Y -95.4% vs S&P 500 +85.1%.
Analysts (BCTX)
Consensus None.
Total return (dividends reinvested) (BCTX)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -69.4% | -95.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -69.5% | -45.9% |
| Volatility (annualized) | 126.2% | 152.9% |
| Max drawdown | -80.1% (Oct 2025→Jun 2026) | -97.7% (Apr 2022→Jun 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 3.77 |
|---|---|
| Change | ▲ 2.03% (up) |
| Previous Close | USD 3.69 |
| Open | USD 3.7 |
| Day Range | USD 3.7 – 3.81 |
| 52-Week Range | USD 2.6 – 14.68 |
| Volume | 34,328 shares |
| Market Cap | $32.75M |
| Exchange | NCM |
Technical Analysis (BCTX)
Nexqual's technical model rates BCTX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.68 (neutral) |
| vs SMA50 | Below (USD 3.8) |
| MACD | -0.01 (negative) |
Analyst Ratings (BCTX)
Wall Street analysts rate BCTX "None", per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | None |
|---|
Earnings (BCTX)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-07-31 | USD 0.04 vs est -12.11 ▲ beat |
| 2025-04-30 | USD -16.4 vs est -17.6 ▲ beat |
| 2025-01-31 | USD -23.3 vs est -19.4 ▼ miss |
| 2024-10-31 | USD -33 vs est -12 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (BCTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -175.25% |
| Current Ratio | 7.07 |
| Total Cash | $22.80M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (BCTX)
Nexqual rates BriaCell Therapeutics Corp.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $23M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$31M (TTM) |
| Efficiency | Critical — ROE -175%, ROA -90.8% |
Ownership (BCTX)
| Insider Ownership | +0.04% |
|---|---|
| Institutional Ownership | +6.39% |
| Shares Outstanding | 8.70M |
| Float | 7.86M |
| Short % of Float | +8.96% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (BCTX)
BriaCell Therapeutics Corp. is led by William V. Williams FCPA (age 70), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO, President & Director | William V. Williams FCPA (age 70) |
|---|---|
| CFO & Corporate Secretary | Gadi Levin B.Com., C.A. (age 52) |
| Chief Scientific Officer | Miguel A. Lopez-Lago (age 55) |
Major Backers & Investors (BCTX)
Notable institutional backers of BriaCell Therapeutics Corp. include Cable Car Capital, LP, Sabby Management, LLC, Iridian Asset Management LLC, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cable Car Capital, LP | 2.49% |
| Sabby Management, LLC | 0.93% |
| Iridian Asset Management LLC | 0.75% |
| UBS Group AG | 0.5% |
| HRT Financial LP | 0.4% |
| Jane Street Group, LLC | 0.3% |
| Luminarx Capital Management LP | 0.17% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt